SuppreMol GmbH, which specialises in autoimmune diseases, has raised €9.5 million as the second part of a €16 million series D financing for the Phase 2 development of its lead autoimmune drug candidate. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
